Sovato has successfully closed its Series B funding round, securing significant capital to accelerate the development and deployment of its remote robotic surgery platform. The company, based in Santa Barbara, California, is pioneering what it describes as the world’s first and only fully remote robotic surgery and procedure system, designed to extend expert surgical care to underserved and remote regions. The funding will support the expansion of Sovato’s technology, including enhancements to its robotic systems, software integration, and clinical validation. The company aims to break down geographic barriers in healthcare by enabling highly skilled surgeons to perform complex procedures from a distance using advanced robotics and real-time data transmission. Sovato’s platform is built on a foundation of precision engineering, low-latency connectivity, and intuitive user interfaces, allowing surgeons to operate with the same dexterity and control as if they were in the same room as the patient. The system is designed to be scalable, modular, and compatible with a range of surgical specialties, with initial focus on minimally invasive and complex general surgery. The company’s leadership emphasizes that the new capital will also be used to strengthen regulatory pathways, expand clinical trials, and build strategic partnerships with hospitals, health systems, and medical device distributors globally. Sovato’s vision is to democratize access to high-quality surgical care, particularly in rural and low-resource areas where specialist surgeons are scarce. By enabling remote procedures, the platform could reduce patient travel, lower healthcare costs, and improve outcomes through consistent, expert-led interventions. The Series B round was led by a group of strategic investors with deep expertise in healthcare innovation, medical technology, and digital health infrastructure. The participation of these investors underscores growing confidence in remote robotic surgery as a transformative force in modern medicine. Sovato continues to work closely with regulatory bodies, including the U.S. Food and Drug Administration, to ensure its platform meets the highest safety and performance standards. The company is on track to begin limited commercial deployment in select medical centers in the near term, with broader rollout planned over the next several years.